

# Optimizing the use of oral iron supplementation in the treatment of iron deficiency anemia

**In most cases, oral iron therapy is first line therapy for iron deficiency anemia. Regimens should be patient-specific and based on tolerability. Oral iron tolerability strategies include using a low starting dose and using an intermittent (every other day) dosing schedule.**

## Background

Iron deficiency is the most common cause of anemia worldwide<sup>1</sup>. Iron deficiency anemia (IDA) is defined as reduced iron levels that occur concurrently with reduced hemoglobin (Hb) levels.

### Goals of treatment include:

1. Symptom improvement
2. Identifying and treating the cause of IDA
3. Restoring Hb concentration and iron stores

The [Towards Optimized Practice \(TOP\) Guidelines for IDA](#) recommend oral iron as the initial and mainstay therapy, with adult target treatment dose of 100-200 mg elemental iron/day<sup>2</sup>. 30-70% of patients on oral iron report GI side effects (e.g., nausea, vomiting, dyspepsia, constipation, diarrhea, dark stools), thereby affecting tolerance and adherence<sup>3,4</sup>. Rates of adverse effects are similar between ferrous salts when equivalent doses of elemental iron are given<sup>2</sup>. Every other day dosing is a good option for those 30-70% who report GI side effects.

Hepcidin is the main hormone that regulates iron absorption. Increased hepcidin levels decrease the amount of iron absorbed from the GI tract, and when hepcidin levels are low, the body is able to increase the amount of iron it can absorb<sup>5,6</sup>. Hepcidin levels are affected by inflammation, the body's iron stores, and genetic factors (e.g. hemochromatosis). There is a negative correlation between oral iron dosing and hepcidin levels, suggesting that as doses of oral iron increase, hepcidin decreases the amount of iron the body can absorb from the GI tract<sup>7</sup>. Unabsorbed iron primarily causes the GI side effects. Alternate day or intermittent dosing of oral iron may improve oral iron absorption and decrease GI side effects<sup>8-10</sup>.

## Guidance<sup>2</sup>

- Oral iron therapy should be used for asymptomatic patients with a Hb >60 g/L
- It takes 3-6 months to replenish iron stores with oral iron therapy
- Oral iron may not be the first choice for patients who are post-bariatric surgery
- Oral iron supplements are Schedule II and require professional intervention from the pharmacist at point of sale. Patients should be made aware that they will need to speak with their pharmacist to obtain a supply
- GI adverse reactions are typically temporary and wane with continuous therapy with the exception of dark stools<sup>4</sup>

## To improve oral iron absorption:

- Approximately 10-20% of an oral iron dose is absorbed at the beginning of therapy<sup>11</sup>
- Oral iron is absorbed to a greater extent on an empty stomach, but administration with food may improve tolerability and adherence<sup>1,4</sup>
- Ascorbic acid may enhance iron absorption; there is no evidence that it is effective in improving IDA<sup>2,12,13</sup>
- Low dose oral iron and intermittent dosing (every other day) may be as effective as standard dose regimens for treating IDA in elderly patients. Limited studies have found significant increases in fractional and total iron absorption and similar increases of Hb and ferritin levels with this approach<sup>8-10</sup>
- To maximize absorption, take oral iron in the morning when hepcidin levels are low and avoid consumption of calcium products or high-oxalate foods (e.g. coffee, tea, spinach)<sup>2</sup>
- Proton pump inhibitor and other acid reduction therapies may decrease oral iron absorption. Consider [deprescribing proton pump inhibitors](#)

## To improve oral iron tolerance:

- Use the lowest effective dose and titrate slowly (at least 4-5 days)<sup>2,4</sup>
- Alternate day or intermittent dosing schedules reduce incidence and severity of GI adverse effects<sup>10</sup>
- Other tolerability strategies<sup>2</sup>:
  - Liquid iron formulation for smaller dose titrations
  - Taking with food
  - Taking at bedtime
  - Try another oral iron formulation, or the iron polysaccharide complex

### In the general population, parenteral iron therapy may be considered when<sup>2</sup>:

- Clinical symptoms of IDA persist and adherence to oral iron therapy was optimized
- Hb continues to decline while on oral iron therapy (<90 g/L)
- Inadequate response (increase in hemoglobin of <10 g/L in 4-6 weeks) to oral iron after 3 months of oral treatment dosing
- Patients continue to suffer intolerance although they have tried a variety of oral iron formulations, including the heme or polysaccharide products

# References

1. DynaMed Plus [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T115986, Iron deficiency anemia in adults; [updated 2018 Nov 30, cited 2019 Jun 12]. Available from <https://www.dynamed.com/topics/dmp~AN~T115986>. Registration and login required.
2. Iron Deficiency Anemia. Clinical Practice Guideline [Internet]. 2018 [cited 2019 Jun 12]. Available from [http://www.topalbertadoctors.org/download/2256/IDA%20CPG.pdf?\\_20190612150337](http://www.topalbertadoctors.org/download/2256/IDA%20CPG.pdf?_20190612150337)
3. Muñoz M, Gómez-Ramírez S & Bhandari S. The safety of available treatment options for iron-deficiency anemia, Expert Opinion on Drug Safety, 2018;17:2, 149-159, DOI: 10.1080/14740338.2018.1400009
4. Guidelines and Protocols Advisory Committee. Iron deficiency – diagnosis and management. Province of British Columbia [Internet]. 2019 [cited 2019 Jun 18]. Available from: <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/iron-deficiency.pdf>
5. Rossi E. (2005). Hcpidin--the iron regulatory hormone. The Clinical biochemist. Reviews, 26(3), 47–49.
6. Kwapisz, J., Slomka, A., & Zekanowska, E. (2009). Hcpidin and Its Role in Iron Homeostasis. EJIFCC, 20(2), 124-128.
7. Joyce J.C. Kroot, Harold Tjalsma, Robert E. Fleming, Dorine W. Swinkels Hcpidin in Human Iron Disorders: Diagnostic Implications. Clinical Chemistry Dec 2011, 57 (12) 1650-1669; DOI: 10.1373/clinchem.2009.140053ba
8. Rimón E, Kagansky N, Kagansky M et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142-1147.
9. Fernández-Gaxiola AC, De-Regil LM. Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women. Cochrane Database Syst Rev 2019;(1):CD009218. doi:10.1002/14651858.CD009218.pub3
10. Stoffel NU, Cercamondi CI, Brittenham G et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017;4: 524–33.
11. Alleyne M, Horne M, Miller J. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121:943.
12. Goddard A, James M, McIntyre A, Scott B, on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency anemia. Gut. 2011;60:1309-16.
13. Diaz M, Rosado JL, Allen LH et al. The efficacy of a local ascorbic acid-rich food in improving iron absorption from Mexican diets: a field study using stable isotopes. Am J Clin Nutr 2003;78:436–40.